Lupin Q4 results: Consolidated net profit rises 35% to Rs 390 cr; income from operations marginally down
Drug firm Lupin has reported a 34.55 percent rise in its consolidated net profit to Rs 389.63 crore for the quarter ended March 2020 mainly on account of robust sales in the domestic market and lower tax expenses
Lupin to divest entire stake in Japanese subsidiary Kyowa Pharma to PE fund Unison Capital Partners for over Rs 3,702 cr
Under the terms of agreement, Lupin's subsidiary Nanomi BV will divest its entire stake in Kyowa to Unison's entity Plutus Ltd for an enterprise value of JPY 57,361
Lupin reports Rs 152 cr loss in Q3 on one-time provisioning for litigation expenses; income from operations rise
On 12 December, 2018, the General Court of the European Union delivered its judgment concerning Lupin's appeal against the European Commission's 2014 decision in a litigation related to Perindopril.
Though everyone wants to sell products at 'exciting' prices cashing in on festival period sales, aggressive discounts can impact the brand’s credibility with the trade
Lupin's net sales rose 34 percent to Rs 4,091.3 crore for the quarter under review compared with Rs 3,054 crore a year earlier
The company had posted a net profit after taxes and minority interest of Rs 624.74 crore for the corresponding period of the previous fiscal, Lupin said in a filing to BSE.
Drug maker Lupin today reported an over 50 percent increase in its net profit for the quarter ended June 30, 2014 on account of robust sales in the US and India.<br />